ICU Medical (ICUI) Expected to Post Quarterly Earnings on Thursday

ICU Medical (NASDAQ:ICUI) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect ICU Medical to post earnings of $2.14 per share and revenue of $552.03 million for the quarter. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to the consensus estimate of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the firm earned $2.10 EPS. On average, analysts expect ICU Medical to post $7.22 EPS for the current fiscal year and $8.05 EPS for the next fiscal year.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $161.83 on Wednesday. The firm has a market capitalization of $4.04 billion, a price-to-earnings ratio of 137.14, a price-to-earnings-growth ratio of 2.04 and a beta of 0.88. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The business’s 50 day simple moving average is $163.40 and its 200-day simple moving average is $149.03. ICU Medical has a 12 month low of $113.37 and a 12 month high of $192.85.

Insiders Place Their Bets

In related news, COO Christian Voigtlander sold 8,929 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the transaction, the chief operating officer directly owned 37,377 shares in the company, valued at $6,837,374.61. The trade was a 19.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ben Sousa sold 2,250 shares of ICU Medical stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $178.32, for a total value of $401,220.00. Following the transaction, the insider owned 3,076 shares of the company’s stock, valued at $548,512.32. This represents a 42.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 21,830 shares of company stock valued at $3,905,003. Corporate insiders own 2.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Needham & Company LLC raised their price objective on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Zacks Research cut ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, KeyCorp raised their price target on ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, ICU Medical has an average rating of “Moderate Buy” and a consensus target price of $192.80.

About ICU Medical

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.